Positron Emission Tomography/Magnetic Resonance (PET/MR): 18F-FDG PET/MR imaging (manufacturer: Siemens, model: Biography mMR). Research devices are marketed products.
Study summary
This study intends to evaluate the application value of Positron Emission Tomography/Magnetic Resonance (PET/MR) in the staging and efficacy evaluation of NK/T cell lymphoma, aiming to explore a more accurate system for predicting the prognosis of patients and guiding the treatment.
Eligibility
Sex
ALL
Min age
14 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria:
* Pathologically diagnosed NK/T-cell lymphoma based on the WHO classification 2016
* Age from 14 to 70 years-old
* ECOG 0-2 score
* Patients with a life expectancy of at least 6 months
* Patient has not been treated before for NK/T cell lymphoma
* Commit to abide by the research procedures and cooperate with the implementation of the whole process of research
* Written informed consent
Exclusion Criteria:
\- Subjects who meet any of the following criteria are not eligible for study entry
* Diagnosed aggressive NK cell leukemia
* Pregnant or lactating women
* Liver and kidney insufficiency
* Other PET/MR contraindications:
1. Those with implanted functional electronic devices such as cardiac pacemakers
2. Carotid aneurysm clipping and other implants are ferromagnetic materials
3. Implanted perfusion devices such as insulin perfusion pumps
4. Those who do not cooperate in examinations such as coma, mental illness, and critically ill patients
5. Those who are claustrophobic
* Other concurrent and uncontrolled medical conditions that the investigator believes will affect the patient's participation in the study
Primary outcome measure(s)
The sensitivity, specificity and accuracy of PET/MR in the staging of newly diagnosed NK/T-cell lymphoma patients — Baseline SUVmax, organs, et al.
The sensitivity, specificity and accuracy of PET/MR in the efficacy evaluation of newly diagnosed NK/T-cell lymphoma patients — After at least 2 cycles SUVmax, organs, et al.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.